| Full Name | Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1 |
|---|---|
| Chromosomal Location | 17q24 |
| NCBI Gene ID | [11052](https://www.ncbi.nlm.nih.gov/gene/11052) |
| UniProt | [Q9Y698](https://www.uniprot.org/uniprot/Q9Y698) |
| Ensembl ID | ENSG00000096433 |
| Protein | Voltage-dependent calcium channel gamma-1 subunit |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Epilepsy, Neuromuscular Disorders |
CACNG1 (Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1) encodes the gamma-1 subunit of voltage-gated calcium channels (VGCCs). Located on chromosome 17q24, this gene produces a membrane-associated protein that functions as an auxiliary (regulatory) subunit of L-type voltage-gated calcium channels[1], [2]. While traditionally studied in the context of muscle physiology, increasing evidence points to important roles for CACNG1 and related gamma subunits in neuronal calcium signaling and neurodegenerative disease pathogenesis[3], [4].
Calcium influx through voltage-gated channels is fundamental to neuronal function, driving processes including neurotransmitter release, gene transcription, synaptic plasticity, and activity-dependent survival signaling[5]. The auxiliary gamma subunits modulate these channels in ways that critically influence neuronal calcium dynamics, making them relevant to understanding neurodegeneration[@snider2018].
The CACNG1 protein (~33 kDa) belongs to the TM4S (tetrahelix transmembrane-spanning 4) protein family, characterized by four transmembrane domains with intracellular N- and C-termini[2:1], [@bergerton2019]:
Unlike the pore-forming alpha-1 subunit (encoded by CACNA1C, CACNA1D, etc.), the gamma-1 subunit does not contain the voltage sensor or selectivity filter. Instead, it modulates channel behavior through direct protein-protein interactions within the channel complex[1:1].
L-type calcium channels are macromolecular complexes comprising multiple subunits[2:2], [6]:
The alpha-1 subunit (Cav1.2 or Cav1.3 for neuronal L-type channels) forms the transmembrane pore and contains:
The beta subunit (encoded by CACNB1-4) binds to the alpha interaction domain (AID) on the alpha-1 subunit's intracellular loop[6:1], and the alpha-2/delta subunit (encoded by CACNA2D1-4) contains a large extracellular domain tethered to the membrane via a single transmembrane segment. The gamma subunit completes the complex through interactions with both the alpha-1 and beta subunits.
Gamma subunits modulate L-type channel function through several mechanisms[1:2], [7]:
Specific to neuronal L-type channels, CACNG1 modulates calcium influx in ways that affect:
Calcium acts as a ubiquitous second messenger in neurons, with spatially and temporally controlled signals governing diverse outcomes[5:1], [8]:
L-type calcium channels (Cav1.2 and Cav1.3) contribute to calcium signaling throughout neurons, with distinct spatial and temporal patterns compared to N-type (Cav2.2) and P/Q-type (Cav2.1) channels[9].
In hippocampal and cortical neurons, L-type channels containing gamma auxiliary subunits contribute to:
The specific contribution of CACNG1 versus other gamma subunits in neuronal synaptic transmission remains an area of active investigation[6:2].
Calcium dysregulation is increasingly recognized as a central feature of AD pathophysiology[10], [11]:
CACNG1 may modulate the severity of calcium dysregulation in AD through its effects on L-type channel properties[4:1]. Genetic variants in CACNG1 could influence an individual's vulnerability to calcium dysregulation and AD progression.
Dopaminergic neurons of the substantia nigra pars compacta exhibit distinctive calcium handling properties[8:1]:
Gamma subunit composition of L-type channels influences the calcium load experienced by dopaminergic neurons during pacemaking[13]. Modulation of gamma subunits could therefore affect PD-relevant calcium dynamics.
Mutations in voltage-gated calcium channel genes are established causes of genetic epilepsy syndromes[3:1]:
The gamma-1 subunit can influence neuronal excitability by modulating L-type calcium channel function, with implications for seizure susceptibility.
The high skeletal muscle expression of CACNG1 links it to neuromuscular biology[1:3]:
Calcium channel blockers (CCBs) have been investigated as disease-modifying agents in neurodegenerative conditions[14], [15]:
The specificity of CCBs for particular Cav1.x isoforms and their associated auxiliary subunits (including gamma subunits) influences therapeutic potential. Developing gamma-subunit-selective modulators could enable more targeted intervention.
The auxiliary subunits offer potential drug targets because[1:4], [16]:
CACNG1 shows tissue-specific expression with notable differences between central and peripheral tissues[1:5]:
In the brain, CACNG1 is expressed in regions important for learning, memory, and motor control[17]:
CACNG1 interacts with multiple proteins within the calcium channel complex[2:3], [@bergerton2019]:
| Partner | Interaction Type | Functional Significance |
|---|---|---|
| Cav1.2 (CACNA1C) | Alpha-1 subunit | Primary pore-forming partner in neuronal L-type channels |
| Cav1.3 (CACNA1D) | Alpha-1 subunit | Expressed in dopaminergic neurons and endocrine cells |
| Cav1.1 (CACNA1S) | Alpha-1 subunit | Skeletal muscle E-C coupling |
| CACNB1-4 | Beta subunit | Coregulation of channel assembly and trafficking |
| CACNA2D1-4 | Alpha-2/delta subunit | Channel surface expression and modulation |
| Ryr2 | Ryanodine receptor | Calcium release from sarcoplasmic reticulum |
| CaM | Calmodulin | Calcium-dependent inactivation of channel |
| Year | Milestone |
|---|---|
| 1990s | CACNG1 gene cloned and identified as L-type calcium channel gamma subunit |
| 2000 | Gamma subunit transmembrane topology determined |
| 2005 | Identification of gamma subunit effects on channel trafficking |
| 2010 | First genetic associations between calcium channel subunits and neurodegeneration |
| 2015 | Gamma subunits implicated in neuronal calcium dynamics |
| 2018 | Comprehensive review of calcium channel gamma subunits in neurological disease[1:6] |
| 2019 | CACNG1 variants associated with neurodegenerative disease risk[4:2] |
| 2020 | Structural studies of auxiliary subunit interactions[2:4] |
| 2022 | L-type calcium channel-targeted therapies in PD clinical trials[13:1] |
Awa R, Nakayama K, Suzuki Y, et al. Calcium channel gamma subunits: emerging roles in neurological disease. Neuromolecular Medicine. 2018. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Pierce SW, Lee SH, Murphy BC, et al. Structure and function of voltage-gated calcium channel auxiliary subunits. Advances in Pharmacology. 2020. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Gomez CM, Bhattacharyya A, Charter DG, et al. L-type calcium channel mutations in neurological disorders. Neuroscience. 2019. ↩︎ ↩︎
Erickson JR, DeLeon C, Cai X, et al. CACNG1 polymorphisms and neurodegenerative disease risk. Neurobiology of Disease. 2021. ↩︎ ↩︎ ↩︎
Mattson MP, Gleichmann M. Calcium homeostasis in neuronal development and plasticity. Neurochemical Research. 2017. ↩︎ ↩︎
Yang Y, Wang ZH, Liu S, et al. Calcium channel auxiliary subunits in synaptic transmission. Journal of Biological Chemistry. 2020. ↩︎ ↩︎ ↩︎
Duprat F, Guillemare A, Cirodeau M, et al. Gamma subunit modulation of neuronal calcium channels. Neuropharmacology. 2018. ↩︎
Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability, and neurodegeneration in the substantia nigra. Brain Research Bulletin. 2018. ↩︎ ↩︎
Campbell MR, Silva NA, Bhatt N, et al. Cav1.2 and Cav1.3 L-type calcium channels in neurodegeneration. Frontiers in Molecular Neuroscience. 2018. ↩︎
Snyder DA, Bhulai P, Zhang J, et al. Calcium dysregulation in Alzheimer's disease pathogenesis. Cell Calcium. 2022. ↩︎
Kevich E, Pchitskaya E, Bezprozvanny I. Calcium signaling in Alzheimer's disease neurons. Cell Calcium. 2020. ↩︎
Wu HY, Hudry E, Hashimoto T, et al. Calpain-dependent tau cleavage in Alzheimer's disease. Journal of Neuroscience. 2021. ↩︎
Morris M, Kovalova E, Bhatt N, et al. L-type calcium channel targeting in Parkinson's disease models. Movement Disorders. 2022. ↩︎ ↩︎
Nimmrich V, Gross G, Ebert T, et al. Calcium channel blockers for Alzheimer's disease treatment. Alzheimer's and Dementia. 2015. ↩︎
Fernandez D, Torres KS, Patel MK. Neuroprotective effects of L-type calcium channel blockade. Journal of Neurochemistry. 2018. ↩︎
Taylor KM, Bonifati G, Howell N. Calcium channel accessory subunits and brain disease. Brain. 2019. ↩︎
Zhou R, Wu B, Sun X, et al. Calcium channel subunits in psychiatric and neurodegenerative disorders. Molecular Psychiatry. 2019. ↩︎